000074867 001__ 74867
000074867 005__ 20200117221644.0
000074867 0247_ $$2doi$$a10.2340/00015555-2918
000074867 0248_ $$2sideral$$a107196
000074867 037__ $$aART-2018-107196
000074867 041__ $$aeng
000074867 100__ $$aBalieva, F.N.
000074867 245__ $$aThe role of therapy in impairing quality of life in dermatological patients: A multinational study
000074867 260__ $$c2018
000074867 5060_ $$aAccess copy available to the general public$$fUnrestricted
000074867 5203_ $$aSkin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3, 846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/ drug reactions (10.2%), psoriasis (9.9%), vasculi-tis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies.
000074867 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000074867 590__ $$a3.531$$b2018
000074867 591__ $$aDERMATOLOGY$$b13 / 66 = 0.197$$c2018$$dQ1$$eT1
000074867 592__ $$a1.125$$b2018
000074867 593__ $$aMedicine (miscellaneous)$$c2018$$dQ1
000074867 593__ $$aDermatology$$c2018$$dQ1
000074867 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000074867 700__ $$aFinlay, A.Y.
000074867 700__ $$aKupfer, J.
000074867 700__ $$0(orcid)0000-0003-1917-6906$$aTomas Aragones, L.$$uUniversidad de Zaragoza
000074867 700__ $$aLien, L.
000074867 700__ $$aGieler, U.
000074867 700__ $$aPoot, F.
000074867 700__ $$aJemec, G.B.E.
000074867 700__ $$aMisery, L.
000074867 700__ $$aKemeny, L.
000074867 700__ $$aSampogna, F.
000074867 700__ $$aVan Middendorp, H.
000074867 700__ $$aHalvorsen, J.A.
000074867 700__ $$aTernowitz, T.
000074867 700__ $$aSzepietowski, J.C.
000074867 700__ $$aPotekaev, N.
000074867 700__ $$aMarron, S.E.
000074867 700__ $$aAltunay, I.K.
000074867 700__ $$aSalek, S.S.
000074867 700__ $$aDalgard, F.J.
000074867 7102_ $$14009$$2735$$aUniversidad de Zaragoza$$bDpto. Psicología y Sociología$$cÁrea Psicolog.Evolut.Educac
000074867 773__ $$g98, 6 (2018), 563-569$$pActa derm.-venereol.$$tACTA DERMATO-VENEREOLOGICA$$x0001-5555
000074867 8564_ $$s366968$$uhttps://zaguan.unizar.es/record/74867/files/texto_completo.pdf$$yVersión publicada
000074867 8564_ $$s139525$$uhttps://zaguan.unizar.es/record/74867/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000074867 909CO $$ooai:zaguan.unizar.es:74867$$particulos$$pdriver
000074867 951__ $$a2020-01-17-22:05:51
000074867 980__ $$aARTICLE